Ephedra is back
American Generics Laboratories has launched four new ephedra-containing weight-loss supplements "as a result of high consumer demand following the recent overturning of the 2004 FDA ban on ephedra-based products," according to an announcement Nov. 16. The Salt Lake City, Utah-based firm was founded in August and is marketing Superdrine RX-10, Ripped Power, Metabothin and Super Ephedra Extreme online for $39.99 - $59.99. "The products are manufactured in FDA-approved facilities and are of daily dosages permitted by law," the firm maintains. FDA banned dietary supplements containing ephedrine alkaloids in 2004. However, a Utah District Court overturned the ban in April for Nutraceutical Corporation's 10 mg product. FDA is appealing the court's decision (1"The Tan Sheet" Nov. 14, 2005, p. 4)...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges